These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31377243)

  • 1. Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.
    Spengler JR; Welch SR; Scholte FEM; Coleman-McCray JD; Harmon JR; Nichol ST; Bergeron É; Spiropoulou CF
    Antiviral Res; 2019 Oct; 170():104573. PubMed ID: 31377243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral replicon particles protect IFNAR
    Spengler JR; Welch SR; Scholte FEM; Rodriguez SE; Harmon JR; Coleman-McCray JD; Nichol ST; Montgomery JM; Bergeron É; Spiropoulou CF
    Antiviral Res; 2021 Jul; 191():105090. PubMed ID: 34044061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models.
    Garrison AR; Shoemaker CJ; Golden JW; Fitzpatrick CJ; Suschak JJ; Richards MJ; Badger CV; Six CM; Martin JD; Hannaman D; Zivcec M; Bergeron E; Koehler JW; Schmaljohn CS
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005908. PubMed ID: 28922426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.
    Hinkula J; Devignot S; Åkerström S; Karlberg H; Wattrang E; Bereczky S; Mousavi-Jazi M; Risinger C; Lindegren G; Vernersson C; Paweska J; van Vuren PJ; Blixt O; Brun A; Weber F; Mirazimi A
    J Virol; 2017 May; 91(10):. PubMed ID: 28250124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice.
    Scholte FEM; Spengler JR; Welch SR; Harmon JR; Coleman-McCray JD; Freitas BT; Kainulainen MH; Pegan SD; Nichol ST; Bergeron É; Spiropoulou CF
    Emerg Microbes Infect; 2019; 8(1):575-578. PubMed ID: 30947619
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model.
    Pavel STI; Yetiskin H; Kalkan A; Ozdarendeli A
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008834. PubMed ID: 33226988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bovine Herpesvirus Type 4 (BoHV-4) Vector Delivering Nucleocapsid Protein of Crimean-Congo Hemorrhagic Fever Virus Induces Comparable Protective Immunity against Lethal Challenge in IFNα/β/γR-/- Mice Models.
    Aligholipour Farzani T; Földes K; Hanifehnezhad A; Yener Ilce B; Bilge Dagalp S; Amirzadeh Khiabani N; Ergünay K; Alkan F; Karaoglu T; Bodur H; Ozkul A
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30857305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Delivery Effect of CD24 on the Immunogenicity and Lethal Challenge Protection of a DNA Vector Expressing Nucleocapsid Protein of Crimean Congo Hemorrhagic Fever Virus.
    Aligholipour Farzani T; Hanifehnezhad A; Földes K; Ergünay K; Yilmaz E; Hashim Mohamed Ali H; Ozkul A
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30658445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.
    Kortekaas J; Vloet RP; McAuley AJ; Shen X; Bosch BJ; de Vries L; Moormann RJ; Bente DA
    Vector Borne Zoonotic Dis; 2015 Dec; 15(12):759-64. PubMed ID: 26684523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Zivcec M; Safronetz D; Scott DP; Robertson S; Feldmann H
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006628. PubMed ID: 30011277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge.
    Leventhal SS; Meade-White K; Rao D; Haddock E; Leung J; Scott D; Archer J; Randall S; Erasmus JH; Feldmann H; Hawman DW
    EBioMedicine; 2022 Aug; 82():104188. PubMed ID: 35907368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.
    Rodriguez SE; Cross RW; Fenton KA; Bente DA; Mire CE; Geisbert TW
    Sci Rep; 2019 May; 9(1):7755. PubMed ID: 31123310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent human plasma candidate reference materials protect against Crimean-Congo haemorrhagic fever virus (CCHFV) challenge in an A129 mouse model.
    Kempster S; Hassall M; Graham V; Kennedy E; Findlay-Wilson S; Salguero FJ; Bagci B; Elaldi N; Oz M; Tasseten T; Charlton FW; Barr JN; Fontana J; Duru C; Ezeajughi E; Matejtschuk P; Arnold U; Adedeji Y; Mirazimi A; Hewson R; Dowall S; Almond N
    Virus Res; 2024 Aug; 346():199409. PubMed ID: 38815869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection.
    Golden JW; Shoemaker CJ; Lindquist ME; Zeng X; Daye SP; Williams JA; Liu J; Coffin KM; Olschner S; Flusin O; Altamura LA; Kuehl KA; Fitzpatrick CJ; Schmaljohn CS; Garrison AR
    Sci Adv; 2019 Jul; 5(7):eaaw9535. PubMed ID: 31309159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.
    Dowall SD; Buttigieg KR; Findlay-Wilson SJ; Rayner E; Pearson G; Miloszewska A; Graham VA; Carroll MW; Hewson R
    Hum Vaccin Immunother; 2016; 12(2):519-27. PubMed ID: 26309231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38.
    Mishra AK; Moyer CL; Abelson DM; Deer DJ; El Omari K; Duman R; Lobel L; Lutwama JJ; Dye JM; Wagner A; Chandran K; Cross RW; Geisbert TW; Zeitlin L; Bornholdt ZA; McLellan JS
    J Virol; 2020 Mar; 94(8):. PubMed ID: 31996434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1.
    Hu YL; Zhang LQ; Liu XQ; Ye W; Zhao YX; Zhang L; Qiang ZX; Zhang LX; Lei YF; Jiang DB; Cheng LF; Zhang FL
    Front Cell Infect Microbiol; 2023; 13():1121163. PubMed ID: 37026060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus.
    Zivcec M; Guerrero LIW; Albariño CG; Bergeron É; Nichol ST; Spiropoulou CF
    Antiviral Res; 2017 Oct; 146():112-120. PubMed ID: 28842265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever.
    Fels JM; Maurer DP; Herbert AS; Wirchnianski AS; Vergnolle O; Cross RW; Abelson DM; Moyer CL; Mishra AK; Aguilan JT; Kuehne AI; Pauli NT; Bakken RR; Nyakatura EK; Hellert J; Quevedo G; Lobel L; Balinandi S; Lutwama JJ; Zeitlin L; Geisbert TW; Rey FA; Sidoli S; McLellan JS; Lai JR; Bornholdt ZA; Dye JM; Walker LM; Chandran K
    Cell; 2021 Jun; 184(13):3486-3501.e21. PubMed ID: 34077751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.